Efficacy of Tympanostomy Tubes for Children with Recurrent Acute Otitis Media
Efficacy of Tympanostomy Tubes for Children with Recurrent Acute Otitis Media
批准号:
9762077
负责人:
ALEJANDRO HOBERMAN
金额:
$91.89万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-07-14 至 2021-06-30
关键词:
15 year old3 year oldAcademyAcuteAdverse effectsAdverse eventAffectAgeAmericanAnesthesia proceduresAntibioticsBeliefChildChild health careChildhoodCicatrixClinical TrialsCoupledDataDecision MakingDevelopmentDiagnosisDiagnosticDoseEarEligibility DeterminationEnrollmentExposure toGoalsGranulation TissueHealthcareImageLifeMedicalMethodologyMiddle Ear VentilationNatureNewborn InfantOperative Surgical ProceduresOtitis MediaOtorrheaParentsPearPediatricsPerforationPerformancePhasePredispositionProceduresProphylactic treatmentRandomizedRandomized Clinical TrialsRecording of previous eventsRecurrenceResearchResistanceResourcesRiskSerotypingSeveritiesSpecimenSubgroupSymptomsTestingTimeTrainingTubeTympanic membraneTympanostomyUncertaintyUnited StatesUnited States Food and Drug Administrationage groupagedanesthesia complicationantimicrobialbacterial resistancebasecare costsclinical practicecostcost effectivecost effectivenessdigitalefficacy studyevidence baseevidence based guidelinesexperiencefollow-uphigh riskinclusion criteriainnovationmiddle earoperationprematurepreventprospectivepublic health relevancerespiratoryrisk benefit ratiotreatment grouptrial comparing
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Tympanostomy tube placement (TTP) for recurrent acute otitis media (rAOM) is frequently performed in children under 3 years of age; however, a critical need exists to establish its risk/benefit ratio. Seventy percent of children experience at
least one episode of AOM during the first year of life; 20% of children have rAOM. The efficacy of TTP for preventing rAOM, assumedly by maintaining middle-ear ventilation, remains unclear. Benefits of TTP must be balanced against risks of anesthesia, complications and sequelae of surgery, and cost. Accordingly, the objective of this proposal is to determine the efficacy of TTP in children aged 6-35 months, the group in which rAOM is most troublesome. The central hypothesis is that in children with rAOM, the operation will prove effective over the ensuing 2 years overall, but the benefit in a more severely affected, and therefore higher-risk subgroup may be substantially greater than in a less severely affected subgroup, in whom benefits may not outweigh risks. The rationale for this research is based on a belief that the limited nature of
the benefit of TTP found in earlier clinical trials may have been the result of enrolling children whose illnesses had not been diagnosed using stringent criteria and/or whose ascertainment of episodes had relied on undocumented histories. The primary objective is to determine the extent to which TTP reduces the overall rate of recurrences in children with rAOM over a 2-year period. In a phase 3 randomized, clinical trial, children aged 6-35 months who are at risk for rAOM will be followed prospectively and examined promptly with new respiratory illnesses to accurately document episodes of AOM. A total of 240 children who meet stringent inclusion criteria for rAOM will be eligible to undergo randomization within strata (age and exposure to other children) to receive TTP or nonsurgical management. Children will be followed for 2 years; the average number of episodes of AOM will be documented and compared between groups. The secondary objective is to determine changes following TTP in nasopharyngeal (NP) colonization with resistant bacteria. At the time of randomization and 3 times a year for 2 years, NP specimens will be obtained and cultured. Susceptibility testing and serotyping will be performed, and the proportions of children colonized with resistant bacteria compared between treatment groups. The tertiary objective is to determine cost-effectiveness of TTP. We will calculate both direct medical and nonmedical costs and correlate this with the number of days that each child has AOM symptoms, otorrhea, and any adverse events or complications. The proposed research is innovative, as we will document AOM episodes prospectively using stringent diagnostic criteria and obtain digital tympanic membrane images otoendoscopically to enhance accuracy of observations. Findings of the proposed study will provide clinicians and parents with dependable evidence concerning the overall effects of TTP compared with nonsurgical management in children with rAOM of varying degrees of severity, enabling evidence-based decisions regarding an important component of the children's healthcare.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Moraxella Catarrhalis Infrequently Cultured from Middle Ear Fluid of Children with Acute Otitis Media.
很少从患有急性中耳炎的儿童的中耳液中培养出卡他莫拉氏菌。
DOI:
10.1097/inf.0000000000004028
发表时间:
2023
期刊:
The Pediatric infectious disease journal
影响因子:
--
作者:
[Conway,IsabellaO, Kurs-Lasky,Marcia, Shaikh,Nader]
通讯作者:
Shaikh,Nader
Efficacy of Tympanostomy Tubes for Children with Recurrent Acute Otitis Media
-
批准号:9304783
-
项目类别:
-
资助金额:$95.31万
-
财政年份:2015
-
负责人:ALEJANDRO HOBERMAN
-
依托单位:
Efficacy of Antimicrobials in Young Children with AOM
-
批准号:7243411
-
项目类别:
-
资助金额:$89.08万
-
财政年份:2006
-
负责人:ALEJANDRO HOBERMAN
-
依托单位:
Efficacy of Antimicrobials in Young Children with AOM
-
批准号:7102128
-
项目类别:
-
资助金额:$92.0万
-
财政年份:2006
-
负责人:ALEJANDRO HOBERMAN
-
依托单位:
Efficacy of Antimicrobials in Young Children with AOM
-
批准号:7761009
-
项目类别:
-
资助金额:$21.35万
-
财政年份:2006
-
负责人:ALEJANDRO HOBERMAN
-
依托单位:
Efficacy of Prophylactic Antimicrobials in Children with Vesicoureteral Reflux
-
批准号:7457904
-
项目类别:
-
资助金额:$58.37万
-
财政年份:2005
-
负责人:ALEJANDRO HOBERMAN
-
依托单位:
Prophylactic Antimicrobials in Children with Vesicoure
-
批准号:7036313
-
项目类别:
-
资助金额:$33.69万
-
财政年份:2005
-
负责人:ALEJANDRO HOBERMAN
-
依托单位:
Efficacy of Prophylactic Antimicrobials in Children with Vesicoureteral Reflux
-
批准号:7645739
-
项目类别:
-
资助金额:$58.36万
-
财政年份:2005
-
负责人:ALEJANDRO HOBERMAN
-
依托单位:
RIVUR - Randomized Intervention for Children with Vesicoureteral Reflux
-
批准号:8123305
-
项目类别:
-
资助金额:$80.95万
-
财政年份:2005
-
负责人:ALEJANDRO HOBERMAN
-
依托单位:
Efficacy of Prophylactic Antimicrobials in Children wit*
-
批准号:7127229
-
项目类别:
-
资助金额:$8.33万
-
财政年份:2005
-
负责人:ALEJANDRO HOBERMAN
-
依托单位:
RIVUR - Randomized Intervention for Children with Vesicoureteral Reflux
-
批准号:8323110
-
项目类别:
-
资助金额:$80.95万
-
财政年份:2005
-
负责人:ALEJANDRO HOBERMAN
-
依托单位:
Efficacy of Prophylactic Antimicrobials in Children with Vesicoureteral Reflux
-
批准号:7243339
-
项目类别:
-
资助金额:$47.8万
-
财政年份:2005
-
负责人:ALEJANDRO HOBERMAN
-
依托单位:
RIVUR - Randomized Intervention for Children with Vesicoureteral Reflux
-
批准号:7992052
-
项目类别:
-
资助金额:$56.81万
-
财政年份:2005
-
负责人:ALEJANDRO HOBERMAN
-
依托单位:
ORAL VS IV TREATMENT OF PYELONEPHRITIS IN CHILDREN 1 TO 12 MONTHS
-
批准号:6115528
-
项目类别:
-
资助金额:$2.06万
-
财政年份:1998
-
负责人:ALEJANDRO HOBERMAN
-
依托单位:
ORAL VS IV TREATMENT OF PYELONEPHRITIS IN CHILDREN 1 TO 12 MONTHS
-
批准号:6276762
-
项目类别:
-
资助金额:$1.51万
-
财政年份:1997
-
负责人:ALEJANDRO HOBERMAN
-
依托单位:
PREVALENCE OF URINARY TRACT INFECTION
-
批准号:3849321
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:ALEJANDRO HOBERMAN
-
依托单位:
COST EFFECTIVENESS OF THIRD GENERATION CEPHALOSPORIN FOR TREATMENT OF UTI
-
批准号:5219300
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:ALEJANDRO HOBERMAN
-
依托单位:--
PHARMACOKINETICS OF CEFIXIME IN INFANTS AGES 1 TO 6 MONTHS
-
批准号:5219316
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:ALEJANDRO HOBERMAN
-
依托单位:--
COST-EFFECTIVENESS OF THIRD GENERATION CEPHALOSPORIN FOR TREATMENT OF UTI
-
批准号:3763531
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:ALEJANDRO HOBERMAN
-
依托单位:
COST-EFFECTIVENESS OF THIRD GENERATION CEPHALOSPORIN FOR TREATMENT OF UTI
-
批准号:3785614
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:ALEJANDRO HOBERMAN
-
依托单位:
海外基金